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OncogeneThis study was designed to detect miR-575 expression and function in non-small cell lung cancer
(NSCLC). A higher expression of miR-575 in NSCLC tissues was observed compared with adjacent
non-neoplastic tissues. Furthermore, re-introduction of miR-575 signiﬁcantly promoted cell
proliferation, migration, and invasion in the NSCLC line. Moreover, we showed that BLID is
negatively regulated by miR-575 at the posttranscriptional level, via a speciﬁc target site within
the 30UTR. Overexpression of BLID counteracted miR-575-induced proliferation and invasion in
NSCLC cells. The expression of BLID is frequently downregulated in NSCLC tumors and cell lines
and inversely correlates with miR-575 expression. The ﬁndings of this study contribute to the
current understanding of the functions of miR-575 in NSCLC.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lung cancer is the most frequent cause of cancer-related death
in many countries [1]. Approximately 85% of all lung cancer cases
are categorized as non-small lung cancer (NSCLC) [2]. Although the
survival rate for lung cancer has increased because of improvement
in diagnosis and treatment, the prognosis of NSCLC remains poor
[3]. Lung carcinogenesis is a multistep process, involving activation
of oncogenes and inactivation of tumor suppressor genes [4]. To
date, the molecular network of lung carcinogenesis remains only
partly clariﬁed [5]. Therefore, a better understanding of the
molecular mechanisms in NSCLC will be helpful to develop novel
therapeutic targets and strategies for the treatment of human
NSCLC [6].
MicroRNAs (miRNAs) are endogenous single-stranded
non-coding RNA that regulate gene expression by base pairing
with target mRNAs, leading to mRNA cleavage or translational
repression [7,8]. Through these mechanisms, miRNAs regulate up
to 30% of human genes and have a major inﬂuence on various
biological processes, including cell differentiation, proliferation,apoptosis, stress resistance, fat metabolism, and development
[9–11]. Many reports have proved a role of miRNAs in the etiology
and pathogenesis of cancer [12]. MiRNAs are frequently deregulat-
ed in many types of cancer such as gastric cancer, breast cancer,
and hepatocellular cancer [13–15]. Recently, increasing evidence
has shown that miRNAs are also involved in NSCLC pathogenesis,
providing new insights for NSCLC treatment [16,17].
Extensive researches have shown that miR-575 was deregulat-
ed and functioned as an oncogene in many tumors, including
gastric cancer, lymphoblastic cancer, and leukemia [18–20].
However, the role of miR-575 in NSCLC cell remains unclear. In this
study, we demonstrated that increased miR-575 expression was a
characteristic molecular change in NSCLC. We also showed that
miR-575 promoted growth and invasion of NSCLC cell, functioning
as an oncogene by directly targeting BLID.
2. Materials and methods
2.1. Ethics statement
All of these patients agreed to participate in the study and gave
written informed consent. Both this study and consent were
approved by the ethical board of the institute of The Second
806 H. Wang et al. / FEBS Letters 589 (2015) 805–811Afﬁliated Hospital of Harbin Medical University and complied with
the Declaration of Helsinki.
2.2. Patients and tumor samples
Twenty primaries NSCLC and their corresponding adjacent
non-tumour lung tissues samples (located > 3 cm from the tumor)
from the same specimens were collected from the The Second
Afﬁliated Hospital of Harbin Medical University from 2011 to
2013. No patients had received blood transfusion, radiotherapy,
or chemotherapy before surgery. Tissue samples were cut into
two parts, one ﬁxed with 10% formalin for histopathological diag-
nosis, and the other snap-frozen in liquid nitrogen, and stored in
liquid nitrogen until RNA extraction.
2.3. Cell culture
Four Human NSCLC cell lines, A549, SPC-A1, H1299, and H1650,
and immortalized human bronchial epithelial cell line 16HBE were
obtained from the Chinese Academy of Sciences (Shanghai, China).
Cells were grown in DMEM media (Invitrogen, Carlsbad, CA, USA)
containing 10% FBS at 37 C with 5% CO2.
2.4. Plasmids and cell transfection
MiR-575 mimic/inhibitor and controls were purchased from
RiboBio (Guangzhou, China). A549 cells were seeded in six-well
plates at 30% conﬂuence one day prior to transfection.
Transfection with miR-575 mimic/inhibitor or the controls was
performed using Lipofectamine 2000 reagent (Invitrogen,Fig. 1. The expression of miR-575 was up-regulated in NSCLC. (A) The two patients wh
expression relative expression levels were determined by qRT-PCR in Human NSCLC ce
16HBE. (C) qRT-PCR analysis of miR-575 expression in 20 pairs NSCLC tissues and th
normalized to U6 snRNA. (D) Relative miR-575 expression levels in NSCLC tissues and th
the signiﬁcant differences between the tumor and normal tissues. ⁄⁄⁄P < 0.001.Carlsbad, CA, USA) according to the manufacturer’s instructions
and transfected into the cells to a ﬁnal oligonucleotide concentra-
tion of 10 nmol/l.
2.5. RNA isolation and quantitative real-time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) and reverse transcribed using a reverse tran-
scription kit (Tiangen). The expression of miR-575 was quantiﬁed
by quantiﬁed reverse transcription polymerase chain reaction
(RT-qPCR) using TaqMan microRNA assays (Applied Biosystems).
U6 was used as an internal control. The expression of BLID was
quantiﬁed by RT-qPCR using SYBRGreen assays (Takara, Da-liang,
China) with GAPDH as an internal control. The primers are listed
in Supplementary Table S1.
2.6. Cell proliferation
Cell proliferation was performed using the Cell Counting Kit-8
(CCK8) (Dojindo, Shanghai, China). Cells were cultured in 10%
CCK-8 diluted medium at 37 C until visual color conversion
occurred. Proliferation rates were determined at 0, 24, 48, and
72 h after transfection. Optical density (OD) values were
determined at a wavelength of 450 nm.
2.7. Cell migration and invasion assay
For the migration assays, cells (5  104) were added into the
upper chamber of the insert (BD Bioscience, 8-lm pore size). For
the invasion assays, cells (1  105) were added into the uppero were diagnosed as NSCLC in H&E staining (original magniﬁcation, 100). (B) The
ll lines (A549, SPC-A1, H1299 and H1650) and normal bronchial epithelial cell line
eir corresponding adjacent normal lung tissues. The expression of miR-575 was
eir corresponding adjacent normal lung tissues. Student’s t test was used to analyze
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both assays, cells were plated in medium without serum, and
medium containing 10% FBS in the lower chamber as chemoattrac-
tant. After several hours of incubation, cells that did not migrate or
invade through the pores were carefully wiped out with cotton
wool. Then the inserts were stained with 20% methanol and 0.2%
crystal violet, imaged, and counted with an IX71 inverted micro-
scope (Olympus).
2.8. Luciferase assays
HEK293T cells (8000 cells per well) were seeded in 96-well
plates the day before transfection. A mixture of 100 ng indicated
BLID-30UTR, 200 ng of BLID or BLID-miR-575 and 20 ng Renilla plas-
mid (containing no 30UTR) was transfected into HEK293T cells with
Lipofectamine 2000 in eachwell. Forty-eight hours later, Fireﬂy and
Renilla luciferase activities were measured using a Dual-Luciferase
Reporter System (Promega). The Renilla luciferase activities were
used as an internal control for transfection efﬁciency.
2.9. Rescue assays of BLID gene expression
The full-length BLID cDNA (which included the ORF and 30-UTR)
was PCR-ampliﬁed and cloned into the pcDNA3.1 vector to gener-
ate the pcDNA-BLID constructs. Cells in 6-well plates were ﬁrst
transfected with either the miR-575 or a scrambled dsRNAFig. 2. Overexpression of miR-575 promoted proliferation, migration and invasion of NS
575 mimics, inhibitors or scramble or no transfection. (B) The CCK8 assay used to eva
inhibitors or scramble or no transfection. (C) Migration assays of A549 cells after treatmen
migratory cells per ﬁeld is shown. (D) Transwell analysis of A549 cells after treatment
invasive cells per ﬁeld is shown below, ⁄P < 0.05, ⁄⁄P < 0.01, and ⁄⁄⁄P < 0.001.(20 nM). After 24 h in culture, these cells were then
co-transfected with 2 lg of the pcDNA-BLID plasmid DNA or with
2 lg of the pcDNA empty vector plasmid. At the indicated time,
cells were harvested and assayed.
2.10. Western blot
Protein was isolated from cell and tissues using the M-PER
Mammalian Protein Extraction Reagent (Pierce Biotechnology,
Rockﬁeld, IL). Protein concentration was detected by the Pierce
BCA assay (Thermo Fisher, Rockford, IL, USA). Equal amounts of cell
lysate were resolved by SDS–PAGE and transferred to PVDF
membranes (Bio-Rad, Hercules, CA, USA). Membranes were
blocked with the following antibodies: rabbit anti-BLID (1:2000,
Cell Signaling, Danvers, MA, USA), rabbit anti-GAPDH (1:5000,
Santa Cruz, Dallas, TX, USA). Bound antibodies were detected with
secondary HRP-conjugated antibodies (Santa Cruz) and visualized
by Pierce enhanced chemiluminescent substrate (Thermo Fisher).
3. Result
3.1. miR-575. was up-regulated in human NSCLC specimens and cell
lines
The two patients who were diagnosed as NSCLC in H&E staining
(Fig. 1A). miR-575 levels were frequently upregulated in NSCLC cellCLC cells. (A) qRT-PCR analysis of miR-575 expression after the transfection of miR-
luate the proliferation of A549 cells after transfection with the miR-575 mimics,
t with miRNA mimics, inhibitors or scramble or no transfection; the relative ratio of
with miRNA mimics, inhibitors or scramble or no transfection; the relative ratio of
808 H. Wang et al. / FEBS Letters 589 (2015) 805–811lines compared with normal bronchial epithelial cell line (Fig. 1B).
In addition, we tested miR-575 expression in NSCLCs obtained
from 20 patients. As shown in Fig. 1C, 95% (19 of 20) of carcinoma
tissues showed increased miR-575 expression compared with
normal counterparts, and the average expression level in carcino-
ma tissues (combination) was signiﬁcantly higher compared with
normal lung tissues (P < 0.001, Fig. 1D).
3.2. miR-575. promoted NSCLC cell proliferation, migration and
invasion
We next evaluated the effects of miR-575 on the proliferation,
migration and migration of A549 cells using the CCK8, the
migration assays and Transwell assay. NSCLC cells were transfect-
ed with scrambled control oligo or miR-575 mimics and inhibitors,
which exhibited high transfection efﬁciency (Fig. 2A). A549 cells
transfected with miR-575 mimic showed increased proliferation
(Fig. 2B); in contrast, knockdown of miR-575 had the opposite
effect on cell proliferation (Fig. 2B). Moreover, the percentage of
migrated cells was higher in cells transfected with miR-575 mimic
and lower in cells transfected with miR-575 inhibitor (Fig. 2C).
Furthermore, the percentage of invasive cells was signiﬁcantly
higher in cells transfected with miR-575 mimic and lower in cells
transfected with miR-575 inhibitor (Fig. 2D). Taken together, these
results demonstrated that miR-575 promoted cell proliferation,
migration and invasion in NSCLC cell.Fig. 3. miR-575 targeted BLID in NSCLC cells. (A) The sequences of miR-575 binding sit
BLID-WT represent the reporter constructs containing the entire 30UTR sequences of BLI
The analysis of the relative luciferase activities of BLID-WT, BLID-MUT. The error bars are
in A549 cells after treatment with miRNA mimics or scramble or no transfection. The
expression in A549 cells transfected with miR-575 mimics or scramble or no transfectio
expression in A549 cells transfected with miR-575 inhibitor or control or scramble. GAP3.3. miR-575. directly targeted BLID 30UTR and negatively regulates its
expression
To determine the target gene of miR-575 on NSCLC cells,
miRDB, micrrna.org and PicTar were used to predict the potential
targets of miR-575. As shown in Fig. 3A, there was complemen-
tarity between has-miR-575 and the BLID 30UTR. We further used
luciferase reporter assay to conﬁrm the direct regulation of BLID
by miR-575 in NSCLC cell lines. Overexpression of miR-575 in
A549 cells resulted in decreased luciferase expression (Fig. 3B). In
addition, miR-575 mimics decreased BLID expression in NSCLC cell
line (. and miR-575 inhibitor can increased the expression of BLD in
NSCLC cell line Fig. 3C and Fig. 3D and E). These results suggested
that miR-575 regulated endogenous BLID expression at least
partially by degrading its mRNA in NSCLC cells.
3.4. Overexpression of BLID impaired the miR-575-induced promotion
of proliferation and invasion
We performed rescue experiments to further validate that BLID
was involved in the function of miR-575 in NSCLC cells. The BLID
expression vector pcDNA3.1-BLID was used to restore BLID expres-
sion. The expression of BLIDwas reducedwhen cellswere transfect-
ed with pcDNA-BLID and miR-575 mimic after 24 h (Fig. 4A).
Ectopic expression of BLID decreased cell proliferation and
migration (Fig. 4B and C; see group pcDNA-BLID + Scramble andes within the human BLID 30UTRs and schematic reporter constructs, in this panel,
D. BLID-MUT represent the reporter constructs containing mutated nucleotides. (B)
derived from triplicate experiments. (C) qRT-PCR analysis of BLID mRNA expression
expression of BLID was normalized to GAPDH. (D) Western blot analysis of BLID
n. GAPDH was also detected as a loading control. (E) Western blot analysis of BLID
DH was also detected as a loading control.
Fig. 4. Overexpression of BLID impaired miR-575-induced proliferation and invasion in NSCLC cell. (A) Western blot analysis of BLID expression in A549 cells co-transfected
with either miR-575 mimics or scramble and pCDNA-BLID or pCDNA empty vector; GAPDH was also detected as a loading control. (B) The CCK8 assay used to evaluate the
proliferation of A549 cells transfected with different combinations. (C) Invasion analysis of A549 cells treated with different combinations. The relative ratio of invasive cells
per ﬁeld is shown right. ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
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(Fig. 4B) was accompanied by decreased cell invasion (Fig. 4C).
Thus, we concluded that the promotion of cell growth and invasion
by miR-575 was a consequence of decreased BLID expression in the
NSCLC cells.
3.5. BLID was inversely expressed with miR-575 in NSCLC and normal
tissues
ThemRNA and protein expression of BLID was frequently down-
regulated in NSCLC cell lines (A549, SPC-A1, H1299, and H1650)
compared with immortalized human bronchial epithelial cell line
(16HBE) (Fig. 5A and B). BLID mRNA was expressed at lower levels
(100%) in tumor tissues compared with normal tissues (Fig. 5C).
Furthermore, the protein levels of BLID in NSCLC were also lower
compared with adjacent normal lung tissues by western blot
(Fig. 5C). As shown in Fig. 5E, when the BLID levels were plotted
against miR-575 expression, a signiﬁcant inverse correlation was
obtained (two-tailed Pearson’s correlation analysis, r = 0.83;
P < 0.01).
4. Discussion
Recent studies have revealed that miRNAs regulate the expres-
sion of many genes involved in lung disease, including cellular
stress, cell differentiation, proliferation and invasion [21–23].
NSCLC is a multistep process with complex mechanisms. A betterunderstanding of the detailed mechanisms might be useful to ﬁnd
new therapeutic targets and strategies for the treatment of NSCLC.
Our research indicated that the expression of miR-575 was higher
in NSCLC tissues than in matched normal lung tissues. In addition,
overexpression miR-575 increased cell proliferation, migration and
invasion in NSCLC cells. Moreover, we also identiﬁed BILD as a
direct target of miR-575. Our ﬁndings, together with those other
groups, suggest that miR-575 has a fundamental role in NSCLC
tumorigenesis by promoting cell proliferation and invasion.
Although miR-575 was reported to associate to
EBV-transformed lymphoblastoid, and gastric cancer [18–
20,24,25], its expression in NCSLC remains to be determined. As
shown in this report, the expression of miR-575 was higher in
NCSLC than the corresponding normal adjacent tissues. To assess
the role of miR-575 in NSCLC development, we investigated the
function effects of miR-575 on various aspects of NSCLC biology,
including cell proliferation, migration and invasion. Inhibition
expression of miR-575 inhibited NSCLC cell proliferation,
migration and invasion. These results suggest that miR-575 might
act as a new oncogene whose up-regulation contributes to the
progression and metastasis of NCSLC.
In this study, we used four miRNA target prediction algorithms
to identify the potential targets of miR-575. Complementary
sequence of miR-575 is identiﬁed in the 30UTR of BLID mRNA.
BLID 30UTR reporter experiment showed a signiﬁcant decrease in
luciferase activity when contransfected with miR-575. And BLID
protein and mRNA was downregulated in miR-575 overexpression
Fig. 5. BLID was inversely expressed with miR-575 in NSCLC. (A) The BLID relative mRNA expression levels were determined by qRT-PCR in Human NSCLC cell lines (A549,
SPC-A1, H1299 and H1650) and normal bronchial epithelial cell line 16HBE. (B) Western blot analysis of BLID expression in Human NSCLC cell lines (A549, SPC-A1, H1299 and
H1650) and normal bronchial epithelial cell line 16HBE. (C) qRT-PCR analysis of BLID expression in 20 pairs NSCLC tissues and their corresponding adjacent normal lung
tissues. The expression of BLID was normalized to GAPDH. (D) Expression of BLID in NSCLC tissues was lower than that in adjacent normal lung tissues. (E) Analysis of
correlation of miR-575 and BLID expression in NSCLC tissues. (Two-tailed Pearson’s correlation analysis, r = 0.83; P < 0.01). Data was presented as log 10 of fold change of
NSCLC tissues relative to non-tumor adjacent tissues.
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results strongly indicated that miR-575 regulated BLID in NSCLC.
BLID (BH3-like motif containing, cell death inducer) was ﬁrst
reported in 2004 in MDA-MB 231 human breast cancer cells
[26,27]. Previous studies showed that BLID acted as a new tumor
suppressor and inhibited breast cancer cell growth and metastasis
via downregulating AKT pathway [28]. Also, BLID was an indepen-
dent prognostic factor for overall survival and distant
metastasis-free survival [29,30]. All these data strongly support a
role for BLID as a new tumor suppressor gene. However, the
expression and role of BLID in NSCLC remain to be determined.
In this study, we indicated that the expression of BLID was lower
in NSCLC tissues than in matched normal lung tissues. In addition,
restored expression of BLID suppressed cell proliferation and inva-
sion in NSCLC cells. However, the underlying mechanisms are still
unclear. For NSCLC, we ﬁrst demonstrated that miR-575 was a new
modulatory regulator of BLID expression in NSCLC, providing one
potential mechanism for role of miR-575 in NSCLC development.
5. Conclusion
In conclusion, we demonstrated that upregulated miR-575 was
a common event in NSCLC and might function as an oncogene by
directly targeting BLID. To the best of our knowledge, this is theﬁrst study to demonstrate that the miR-575/BLID axis regulates
the proliferation, migration and invasion of NSCLC cells. These
ﬁndings provide a better understanding of the pathogenesis and
development of NSCLC. The miR-575/BLID axis may provide an
important target for future therapy of the NSCLC.
6. Competing interests
The authors declare that they have no competing interests.
7. Authors’ contributions
Conceived and designed the experiments: Hongwei Wang,
Chunhua Yan, Xiaodong Shi, Jiaolin Zheng, Lili Deng, Lei Yang,
Fangfei Yu, Yuxia Shao, Yuandi Yang. Performed the experiments:
Hongwei Wang, Chunhua Yan. Analyzed the data: Hongwei
Wang, Chunhua Yan. Contributed reagents/materials/analysis
tools: Yuxia Shao. Wrote the paper: Hongwei Wang, Chunhua Yan.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2015.02.
013.
H. Wang et al. / FEBS Letters 589 (2015) 805–811 811References
[1] Shi, W.Y., Liu, K.D., Xu, S.G., Zhang, J.T., Yu, L.L., Xu, K.Q. and Zhang, T.F. (2014)
Gene expression analysis of lung cancer. Eur. Rev. Med. Pharmacol. Sci. 18,
217–228.
[2] Ma, L. et al. (2011) An integrated analysis of miRNA and mRNA expressions in
non-small cell lung cancers. PLoS ONE 6, e26502.
[3] Yang, Y., Liu, L., Zhang, Y., Guan, H., Wu, J., Zhu, X., Yuan, J. and Li, M. (2014)
MiR-503 targets PI3K p85 and IKK-beta and suppresses progression of
non-small cell lung cancer. Int. J. Cancer 135, 1531–1542.
[4] Yu, T. et al. (2014) MicroRNA-193a-3p and -5p suppress the metastasis of
human non-small-cell lung cancer by downregulating the
ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene 34, 413–423.
[5] Liloglou, T., Bediaga, N.G., Brown, B.R., Field, J.K. and Davies, M.P. (2014)
Epigenetic biomarkers in lung cancer. Cancer Lett. 342, 200–212.
[6] Reungwetwattana, T. and Dy, G.K. (2013) Targeted therapies in development
for non-small cell lung cancer. J. Carcinog. 12, 22.
[7] Truini, A. et al. (2014) Role of microRNAs in malignant mesothelioma. Cell.
Mol. Life Sci. 71, 2865–2878.
[8] Fernandez-Hernando, C., Ramirez, C.M., Goedeke, L. and Suarez, Y. (2013)
MicroRNAs in metabolic disease. Arterioscler. Thromb. Vasc. Biol. 33, 178–185.
[9] Rotllan, N. and Fernandez-Hernando, C. (2012) MicroRNA regulation of
cholesterol metabolism. Cholesterol 2012, 847849.
[10] Rottiers, V. et al. (2011) MicroRNAs in metabolism and metabolic diseases.
Cold Spring Harb. Symp. Quant. Biol. 76, 225–233.
[11] Najaﬁ-Shoushtari, S.H. (2011) MicroRNAs in cardiometabolic disease. Curr.
Atheroscler. Rep. 13, 202–207.
[12] Lu, J. et al. (2005) MicroRNA expression proﬁles classify human cancers.
Nature 435, 834–838.
[13] Zheng, F. et al. (2012) The putative tumour suppressor microRNA-124
modulates hepatocellular carcinoma cell aggressiveness by repressing
ROCK2 and EZH2. Gut 61, 278–289.
[14] Shimoda, M., Takahashi, M., Yoshimoto, T., Kono, T., Ikai, I. and Kubo, H. (2006)
A homeobox protein, prox1, is involved in the differentiation, proliferation,
and prognosis in hepatocellular carcinoma. Clin. Cancer Res. 12, 6005–6011.
[15] Teng, Y., Mei, Y., Hawthorn, L. and Cowell, J.K. (2014) WASF3 regulates
miR-200 inactivation by ZEB1 through suppression of KISS1 leading to
increased invasiveness in breast cancer cells. Oncogene 33, 203–211.
[16] Shi, L., Jackstadt, R., Siemens, H., Li, H., Kirchner, T. and Hermeking, H. (2014)
P53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to
regulate epithelial-mesenchymal transition and metastasis in colorectal
cancer. Cancer Res. 74, 532–542.[17] Yu, H., Jiang, L., Sun, C., Li Guo, L., Lin, M., Huang, J. and Zhu, L. (2014)
Decreased circulating miR-375: a potential biomarker for patients with
non-small-cell lung cancer. Gene 534, 60–65.
[18] Yao, Y. et al. (2009) MicroRNA proﬁling of human gastric cancer. Mol. Med.
Rep. 2, 963–970.
[19] Pizzimenti, S., Ferracin, M., Sabbioni, S., Toaldo, C., Pettazzoni, P., Dianzani,
M.U., Negrini, M. and Barrera, G. (2009) MicroRNA expression changes during
human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a
product of lipid peroxidation. Free Radic. Biol. Med. 46, 282–288.
[20] Lee, J.E., Hong, E.J., Nam, H.Y., Hwang, M., Kim, J.H., Han, B.G. and Jeon, J.P.
(2012) Molecular signatures in response to Isoliquiritigenin in lymphoblastoid
cell lines. Biochem. Biophys. Res. Commun. 427, 392–397.
[21] Gu, H., Yang, T., Fu, S., Chen, X., Guo, L. and Ni, Y. (2014) MicroRNA-490-3p
inhibits proliferation of A549 lung cancer cells by targeting CCND1. Biochem.
Biophys. Res. Commun. 444, 104–108.
[22] Guo, H., Li, Q., Li, W., Zheng, T., Zhao, S. and Liu, Z. (2014) miR-96
downregulates RECK to promote growth and motility of non-small cell lung
cancer cells. Mol. Cell. Biochem. 390, 155–160.
[23] Ye, X.W., Yu, H., Jin, Y.K., Jing, X.T., Xu, M., Wan, Z.F. and Zhang, X.Y. (2014)
miR-138 inhibits proliferation by targeting 3-phosphoinositide-dependent
protein kinase-1 in non-small cell lung cancer cells. Clin. Respir. J. 9, 27–33.
[24] Gu, H. et al. (2012) Diagnostic role of microRNA expression proﬁle in the
serum of pregnant women with fetuses with neural tube defects. J.
Neurochem. 122, 641–649.
[25] Nardelli, C. et al. (2014) Characterization and predicted role of the microRNA
expression proﬁle in amnion from obese pregnant women. Int. J. Obes. (Lond.)
38, 466–469.
[26] Li, X., Su, P., Liu, X., Kong, X., Zhang, X., Zhang, H. and Yang, Q. (2014) Aberrant
BLID expression is associated with breast cancer progression. Tumour Biol. 35,
5449–5452.
[27] Broustas, C.G., Gokhale, P.C., Rahman, A., Dritschilo, A., Ahmad, I. and Kasid, U.
(2004) BRCC2, a novel BH3-like domain-containing protein, induces apoptosis
in a caspase-dependent manner. J. Biol. Chem. 279, 26780–26788.
[28] Li, X., Kong, X., Wang, Y. and Yang, Q. (2013) BRCC2 inhibits breast cancer cell
growth and metastasis in vitro and in vivo via downregulating AKT pathway.
Cell Death Dis. 4, e757.
[29] Zhao, F. et al. (2010) Evaluation of BLID and LOC399959 as candidate genes for
high myopia in the Chinese Han population. Mol. Vis. 16, 1920–1927.
[30] Cavalli, L.R., Noone, A.M., Makambi, K.H., Rone, J.D., Kasid, U.N. and Haddad,
B.R. (2011) Frequent loss of the BLID gene in early-onset breast cancer.
Cytogenet. Genome Res. 135, 19–24.
